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OBJECTIVES: To evaluate utilisation of drugs involved in treatment of NSCLC, its
consumption in terms of expenditures units and number of packages prescribed in
Slovakia within 2008 -2011. METHODS: Statistical analysed data were abstracted
from State Institute for Drug Control SR, studied in accordance with financial units
(€) and number of packages prescribed every year. RESULTS: ATC L01 – antineo-
plastic agents is the one most prescribed out off all anticancer drugs (593 067
packages prescribed in 2011, 105 786 256,10 €). From L01XA platinum cytostatics –
cisplatina is the one most prescribed, with decreasing tendency in financial expen-
ditures spent (45 965 pcgs, 344 601,70 € in 2008 and 56 584 pcgs, 229 525,80 € in 2011)
compared to the least prescribed and most expensive oxiplatina. L01CD taxans –
paclitaxel and docetaxel has decreasing tendency in number of packages pre-
scribed and in financial expenditures. L01BC – the most prescribed fluorouracil has
decreasing tendency, the prescription of gemcitabin stagnates, utilization of kape-
citabin increases in number of packages and in financial units. L01XC monoclonal
antibodies – prescription of bevacizumab had increasing tendency until 2010 (13
405 pcgs, 11 339 764,50 € in 2008, 24 028 pcgs, 18 256 481,00 € in 2010 ), in 2011
prescription of cetuximab was higher than bevacizumab, and less money was
spent (cetuximab: 28 772 pcgs, 5 385 830,90€, bevacizumab: 22 661 pcgs, 17 045
495,70€). L01XE - inhibitors of protein kinase – erlotinib has increasing tendency in
number of packages prescribed and in financial expenditures (1 265 pcgs, 2 895
154,30 € in 2008, 2 071 pcgs, 3 687 581,00 € in 2011), tendency of gefitinib since 2010
when it entered the market is increasing, but it still did not overtook erlotinib (248
pcgs, 545 600,00 € in 2011). CONCLUSIONS: This study proved high economic bur-
den and continually rising amount of expenditures on antineoplastic agents, used
also in treatment of NSCLC.
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OBJECTIVES: To assess availability (patients’ access) to medicines for rare diseases
(Orphan Drugs; ODs) and to determine expenditures in the horizon of 7 years
(within years 2004 – 2010) in absolute figures and relative proportion related to
expenditures of all medicinal products in the Czech Republic (CR). METHODS: We
identified all OD registered until September 2011 by EMA. It was compared the year
of registration with the year of patients’ access to particular OD. Patients’ access to
ODs was defined as availability in official Czech distribution net. From the data-
bases of State Institute for Drug Control (SUKL), expenditures of particular OD
within all relevant years were calculated. RESULTS:Until September 2011, 49 out of
66 EMA registered ODs (74%) have been available. The mean duration of period
between registration year and year of availability in the Czech distribution net
(among already available ODs) was 2.27 years. This period was longer within past
years compared to recent years. The expenditures for ODs revealed an extreme
increase up to year 2007, while in recent years it has been more stable. In particular,
the expenditures (in million EUR) within years 2004 – 2010 were 0.2, 2.5, 12.8, 31.9,
51.2, 66.3 and 83.4, respectively. These expenditures represented 0.8%, 1.8%, 2.3%,
3.0% and 3.6% of total medicine expenditures within years 2006 – 2010 in CR. The
highest burden among all ODs have been represented by medicines for treatment
of Chronic Myeloid Leukemia and Renal Cell Carcinoma, those medicines repre-
sented 48.3% of all expenditures for ODs in 2010. CONCLUSIONS: It must be noted,
not all of available ODs are reimbursed on a standard basis, since some ODs have
conditional or exceptional (per particular patient) reimbursement. The current ex-
penditure for ODs in the CR is approximately 4% of total drugs expenditures, which
is comparable with other EU countries.
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OBJECTIVES: Anti-cancer drugs are often challenged on the ground that most clin-
ical trials show modest gains in terms of overall survival associated with high
acquisition costs. But in the same time, many oncologists make the point that
progress is incremental and should be assessed dynamically on a longer period. We
collected various data over a 20 year period (1990-2010) to provide a retrospective
view of the progress that has been achieved in medical terms and the amount of
public resources that has been spent through better treatments. METHODS: We
constructed two scenarios. The first one is a reconstruction of what actually hap-
pened. On a yearly basis, we follow the patients who reported to have a cancer to
Health Insurance. We computed the incident cases, the number of deaths, the
number of surviving patients and the average and total treatment costs, from the
public payer’s perspective. The second one is a “counterfactual” scenario which
differs only by the assumption that medical progress has stopped in 1990. Efficacy
and cost of medicines are maintained equal to their 1990 values on the whole
remaining period. RESULTS: In that hypothetical scenario, the public payer spares
nearly 60 billions of current Euros over the whole period, compared to the “real
scenario”, partly because of a fewer number of patients to treat, partly because of a
lower average treatment cost. But in the same time, the number of deceased pa-
tients rises by 670,000 and the number of lost years of life by 3.2 million. This means
that retrospectively the medical progress has allowed to save one additional year of
life at a marginal cost of 18,500 €. in current value for the public payer.
CONCLUSIONS: Investing in new and innovative cancer treatments was an effec-
tive and a cost-effective use of public resources in years 1990-2010.
PCN136
EXPENDITURES ON ORPHAN DRUGS IN CANADA, EUROPE (EU5  BELGIUM,
SWEDEN AND THE NETHERLANDS) AND AUSTRALIA IN 2009
Haddad P1, Hurry M2, Barbeau M1
1Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 2Novartis Pharmaceuticals Canada,
Dorval, QC, Canada
OBJECTIVES: To compare expenditures on orphan drugs (OD) in Canada, Europe
(EU5  Belgium, Sweden and Netherlands) and Australia in 2009. METHODS: ODs
were selected for analysis according to the following inclusion criteria: 1) approved
by the European Medicines Agency (EMA) between 2001 and 2011, 2) retained EMA
orphan designation until December 2011, 3) remained available until December
2011, 4) received Canadian marketing authorization, and 5) received a Canadian
Health Technology Assessment (HTA) recommendation between 2006 and 2011.
Utilization and total sales was retrieved from IMS MIDAS data availability. Com-
parison across countries was carried out by deriving the cost/capita (expressed in
CAN$ 2011) and total expenditures were compared to total drug budget as reported
from the Organization for Economic Cooperation and Development (OECD) 2011
report. RESULTS: Of the 18 drugs selected, data on 8 drugs were reported only. In
2009, Canadian cost/capita was among the lowest ($0.29) in the 10 countries while
the highest were in France, Italy and Germany ($0.94; $0.70 and $0.66 respectively).
Differences were noted for oncology and non-oncology drugs, namely expendi-
tures in rare cancers remained among the lowest in Canada ($0.19) while these
expenditures were highest in France, Germany and Italy ($0.76; $0.47 and $0.47
respectively). This trend appears to follow previously reported low access of oncol-
ogy drugs in Canada vs. other developed systems (13/14 countries). France, Sweden
and Italy were associated with the highest percentage of expenditures (0.50%;
0.41% and 0.40% respectively) while the lowest were observed in the UK, The Neth-
erlands and Canada (0.22%; 0.19% and 0.14% respectively). CONCLUSIONS: Canada
was among the lowest in regards to cost/capita and percentage of OD expenditure
compared to total drug expenditures in 10 countries. This is likely explained by the
higher rate of HTA negative recommendations which impacts payer’s decision.
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OBJECTIVES: Health technology appraisal (HTA) recommendations from the UK
National Institute of Health and Clinical Excellence (NICE) are intended to standar-
dise health care throughout the NHS, and hasten the uptake of new, more effective
medicines that are cost-effective. Several studies have investigated whether NICE
guidance influences UK drug uptake as intended, mostly using sales data. However,
this approach does not reveal which indication, line of therapy, nor patient sub-
group a drug has been used to treat. This study aims to avoid these limitations by
using IMS Health’s Oncology Analyzer™ as the primary data source. Oncology
AnalyzerTM contains detailed records for a representative patient sample, allow-
ing analyses to be focussed on the particular indication and treatment criteria
specified in NICE HTAs.METHODS:HTAs for breast cancer drugs appraised by NICE
from 2005 to 2008 were analysed. For each HTA, the proportion of the eligible
patient sub-group that received the recommended (or not recommended) drugs
from Q1 2005 to Q1 2009 was determined. Changes in drug uptake in the relevant
patient populations were assessed for the UK, and were also compared to uptake in
similar European countries. RESULTS: NICE produced 6 HTAs for breast cancer,
encompassing 8 drugs, during the period assessed. In 5 out of 6 cases, the publica-
tion of an HTA was followed by the recommended change in UK drug uptake.
However, when UK uptake of drugs recommended by NICE was compared to up-
take of the same drugs in four other European countries (France, Germany, Italy
and Spain), the UK ranked at the bottom of the group. CONCLUSIONS: The NICE
HTAs assessed were mostly followed by the intended changes in drug uptake,
suggesting they were implemented, at least by some PCTs. Despite this, interna-
tional comparisons of uptake for these drugs revealed that the UK performed
poorly compared to similar European countries.
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OBJECTIVES: Cancer patients receiving chemotherapy are at risk of venous throm-
boembolism (VTE). Information on anticoagulants use in these patients is lacking.
This retrospective cohort study describes the patterns of anticoagulant use in this
population using a US claims database. METHODS: The MarketScan® databases, a
nationwide database covering 30 million patients annually, were used. Adult
cancer patients receiving chemotherapy6 months following the cancer diagnosis
between 2004-2010 were included. Patients with bleeding history before chemo-
therapy were excluded. Six cancer types were assessed: lung, colorectal, pancreas,
bladder, stomach, and ovary. Anticoagulant use 2 weeks before or after chemother-
apy initiation was determined using National Drug Code or Healthcare Common
Procedure Coding Systems. Anticoagulant therapy duration was calculated as the
sum of total injections administered and total days of supply from prescriptions
dispensed within 2-weeks before/after chemotherapy initiation. RESULTS:Overall,
30% (N21,101) of the total patients (N70,822) used anticoagulants within 2 weeks
before/after chemotherapy. Of these, 34% used anticoagulants 2 weeks before only,
30% 2 weeks after only, and 36% in both periods. Users’ median age was 61 years
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